8-K: Horizon Space II Extends Merger Deadline, Secures Funding

Horizon Space Acquisition II Corp. extended its deadline to complete a business combination with SL BIO Ltd. to April 18, 2026, funded by a $50,000 unsecured promissory note from William Wang.

Summary

• Horizon Space Acquisition II Corp. (the "Company") has extended the period to consummate its initial business combination by one month, from March 18, 2026, to April 18, 2026.
• This extension is the second of twelve possible one-month extensions permitted under the Company's amended and restated memorandum and articles of association.
• The extension was enabled by a deposit of $50,000 (the "Extension Fee") into the Company's trust account on or about March 13, 2026.
• The Extension Fee was deposited by Mr. William Wang, who is the Chief Executive Officer of SL BIO Ltd., the target company for the business combination.
• In connection with the Extension Payment, the Company issued an unsecured promissory note of $50,000 (the "Note") to Mr. William Wang on March 17, 2026.
• The Note bears no interest and is payable upon the earlier of the consummation of the business combination or the expiry of the Company's term.
• Mr. Wang has the right, but not the obligation, to convert the Note into private units of the Company at a conversion price of $10.00 per unit, with each unit consisting of one ordinary share and one right to receive one-tenth of one ordinary share.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral development. While the extension provides necessary time, it also highlights ongoing challenges in closing the business combination. The funding mechanism is typical for SPACs in this situation, showing commitment but also the cost of delays.

Positives

• The extension provides additional time for the Company to complete its business combination with SL BIO Ltd., indicating continued efforts to close the deal.
• The $50,000 promissory note is unsecured and non-interest bearing, which is favorable for the Company's immediate financial position.
• The funding for the extension by Mr. William Wang, CEO of the target company, demonstrates commitment from key stakeholders to the proposed business combination.

Negatives

• The need for an extension suggests that the Company is facing challenges in completing its initial business combination within the original timeframe.
• The issuance of a promissory note that can be converted into equity introduces potential future dilution for existing shareholders if Mr. Wang exercises his conversion rights.
• Each extension incurs a cost ($50,000 in this instance), which depletes the Company's resources or increases its liabilities.

Risks

• Failure to consummate the business combination: Despite the extension, there is no guarantee that the Company will successfully complete the merger with SL BIO Ltd. by the new deadline or subsequent extensions.
• Potential dilution from note conversion: If the promissory note is converted into units, it will increase the number of outstanding shares and rights, potentially diluting the ownership percentage of current shareholders.
• Reliance on sponsor/related parties for funding extensions: The Company's ability to secure future extensions may depend on the willingness of the sponsor or related parties to provide additional funding.
• General SPAC risks: The inherent risks associated with SPACs, including the risk of not finding a suitable target or failing to gain shareholder approval for a proposed transaction, remain.

Future Outlook

The Company now has until April 18, 2026, to complete its initial business combination. It retains the option to extend this period up to ten more times, each by an additional one month, until February 18, 2027, subject to further Extension Fee deposits.

Management Comments

• Mr. William Wang, CEO of SL BIO Ltd., deposited $50,000 into the Trust Account to facilitate the extension of the business combination deadline.
• The Company's CEO, Mingyu (Michael) Li, signed the Form 8-K, indicating the official reporting of these events.

Industry Context

StockSavvy.ai notes that SPAC extensions are a common occurrence in the current market environment, often signaling complexities in deal finalization or higher-than-expected shareholder redemptions. The funding of such extensions through promissory notes from sponsors or target company management is a standard practice, reflecting a continued commitment to the transaction despite delays, but also the financial burden of prolonged de-SPAC processes.

Comparison to Industry Standards

• Many SPACs, such as Gores Holdings VIII (GIIX) or Churchill Capital Corp IV (CCIV), have sought multiple extensions to complete their de-SPAC transactions, often involving similar sponsor loans or promissory notes to fund the trust account.
• The $0.033 per share or $50,000 total extension fee is within the typical range for such extensions, which can vary based on the SPAC's size and remaining public shares, aligning with common industry practices for maintaining a SPAC's operational runway.

Corporate Governance

Related Party Transactions

• Issuance of an unsecured promissory note of $50,000 to Mr. William Wang, who is the Chief Executive Officer of SL BIO Ltd., the target company for the business combination. Mr. Wang also deposited the $50,000 Extension Fee into the Trust Account.

Stakeholder Impact

• Shareholders: Face continued uncertainty regarding the business combination's completion, potential future dilution if the promissory note converts, but also benefit from the extended opportunity for the deal to close.
• Creditors: The promissory note is unsecured and explicitly waives claims to the Trust Account Funds, limiting recourse for the payee (Mr. Wang) to funds outside the Trust Account if the business combination is not consummated.
• Management: Demonstrates continued commitment to the business combination by funding the extension, but also indicates the ongoing effort required to finalize the deal.

Next Steps

• The Company must complete its initial business combination with SL BIO Ltd. by April 18, 2026.
• The Company may seek further one-month extensions, up to a total of twelve, until February 18, 2027, by depositing additional Extension Fees into the Trust Account.

Key Dates

Recommendation

The extension provides additional time for the business combination to close, which is a positive for the deal's prospects. However, the need for an extension and the associated costs, even if funded by a related party, indicate ongoing challenges. Investors should hold while awaiting further clarity on the merger's progress and terms, as the outcome remains uncertain.

Keywords

SPAC, Business Combination, Extension, Promissory Note, Horizon Space Acquisition II Corp., SL BIO Ltd., Merger, De-SPAC, Nasdaq